Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Videos|August 24, 2017
Treat-to-Target in Rheumatoid Arthritis
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5